← All organizations
Highest phase reached
Phase 4
First clinical trial
Dec 1, 2002First marketed drug
Jan 1, 1974First NDA
Dec 29, 1992Last known activity
Jun 3, 2026
Timeline
1970s
- Jan 1, 1974
Apotex— Founded
2000s
- Jan 1, 2007
Lareq Pharma— Acquired
2010s
- Jan 1, 2012
Aveva Drug Delivery Systems— Acquired
- Apr 4, 2014
valaciclovir— Marketing Organization
Drugs by trial phase (11 distinct, 33 trials)
Phase 4 (3 own, 0 via acquisition)
Phase 3 (3 own, 0 via acquisition)
Phase 2 (5 own, 0 via acquisition)
Indications
Approved for
Studied for
- Amyotrophic Lateral Sclerosis
- Anemia
- Anemia, Sickle Cell
- Ataxia
- beta-Thalassemia
- Carcinoma, Ovarian Epithelial
- Cerebellar Ataxia
- Friedreich Ataxia
- Hemosiderosis
- HIV Infections
- Iron Overload
- Keratosis
- Keratosis, Actinic
- Liver Diseases
- Motor Neuron Disease
- Nerve Degeneration
- Ovarian Neoplasms
- Pantothenate Kinase-Associated Neurodegeneration
- Parkinson Disease
- Psoriasis
- Renal Insufficiency
- Rhinitis
- Rhinitis, Allergic
- Rhinitis, Allergic, Seasonal
- Sclerosis
- Thalassemia
Marketed drugs (309)
Subsidiaries (2 direct, 2 total across the full acquisition tree)
Recent trials (44)
- NCT04840823CollaboratorPhase 1/Phase 2Mar 26, 2021
- NCT03802916Lead sponsorPhase 2Mar 6, 2019
- NCT03591575Study directorPhase 4Aug 1, 2018
- NCT03591575Lead sponsorPhase 4Aug 1, 2018
- NCT03480776CollaboratorPhase 2Apr 6, 2018
- NCT02728843Lead sponsorPhase 2Jul 1, 2016
- NCT02728843Study directorPhase 2Jul 1, 2016
- NCT02655315CollaboratorPhase 2Feb 1, 2016
- NCT02635841Lead sponsorN/ADec 17, 2015
- NCT02465489Lead sponsorPhase 1Jun 1, 2015
- NCT02456558Lead sponsorPhase 1Jun 1, 2015
- NCT02443545Lead sponsorPhase 4May 1, 2015
- NCT02442310Lead sponsorPhase 1May 1, 2015
- NCT02442310Study chairPhase 1May 1, 2015
- NCT02174848Lead sponsorPhase 3Jun 1, 2014
Details
- Founded
- Toronto, CA Jan 1, 1974
- First NDA
- Dec 29, 1992
- Last known activity
- Jun 3, 2026
Designations held
- Orphan drug
- Priority review
- Accelerated approval